Ipulatifomu ye-DTP yeCaryHealth yenza inqubo yokwelapha i-Natroba (echinococcin) ibe lula ngokufaka esikhundleni sezinqubo zokunakekelwa okubonakalayo ezihlukene ngemodeli engenamthungo, egxile esigulini.
I-WASHINGTON, Ephreli 7, 2026 — (BUSINESS WIRE) — I-CaryHealth, inkampani ehamba phambili yezempilo yedijithali, namuhla imemezele ukubambisana ne-Cipher Pharmaceuticals US LLC (Cipher noma i-Cipher Pharmaceuticals) ukuze yethule ipulatifomu yayo eqondile eya esigulini (i-DTP), eyenzelwe ukunikeza iziguli ukufinyelela okulula kumuthi kadokotela i-Natroba (spinosad), osetshenziselwa ukwelapha izintwala zekhanda kanye nokhwekhwe. Njengengxenye yalokhu kubambisana, i-CaryHealth ithuthukise ipulatifomu ekwi-inthanethi eyenziwe ngokwezifiso evumela iziguli ukuthi zifinyelele futhi zithathe i-Natroba (spinosad) ngokushesha, isuse izithiyo ezivamile iziguli ezibhekana nazo lapho zisebenzisa izinsizakalo zezempilo eziku-inthanethi.
"Imindeni ebhekene nezintwala nezikhwehlela idinga ikhambi elisheshayo nelilula lokuthola imithi kadokotela engcono kakhulu nesebenza kahle kakhulu," kusho uBrian Jacobs, uMongameli we-US Operations for Cipher Pharmaceuticals. "Ngokubambisana kwethu neCaryHealth, sinikeza ukulandwa eceleni komgwaqo noma ukulethwa ekhaya, okwenza kube lula futhi kusheshe ngeziguli ukufinyelela i-Natroba™ noma inguqulo yayo ejwayelekile enelayisensi, i-spinosad. Imithi yendabuko yekhemisi ayisasebenzi, kodwa i-Natroba™ kadokotela (spinosad) inikeza impumuzo ngokushesha ezintwala nezikhwehlela."
"I-Cipher ithatha isinyathelo esinesibindi nesigxile esigulini ngokutshala imali kumodeli yokunakekelwa kwempilo yedijithali ehlangene," kusho u-Areo Nazari, i-CEO ye-CaryHealth. "Ngokuhlanganisa imithi kadokotela, ukuxhumana nodokotela, kanye nezinsizakalo zekhemisi (kufaka phakathi ukulethwa) kokuhlangenwe nakho okukodwa, singasiza imindeni ukuthi ibuyele esimweni esijwayelekile, kusukela ngesikhathi ifuna ukunakekelwa kuze kube yilapho ikwelapha ngempumelelo."
I-CaryHealth ithuthukise ikhambi elihlanganisiwe, elingenamthungo, neliphelele lokunakekelwa kweziguli ngqo kwe-Natroba™ (echinococcin), okwenza ngcono ulwazi lokunakekelwa okuphelele ngokunciphisa izikhathi zokufinyelela nokususa izithiyo. Lesi sixazululo sisusa izinqubo zokunakekelwa okubonakalayo ezingahlangene, ukungena ngemvume okuningi, kanye nezinyathelo zokukhokha ezihlukene, okuvumela iziguli ukuthola imithi kadokotela ephilile kude, zijabulele ukulethwa ngosuku olufanayo kusuka kumakhemisi ezweni lonke endaweni yesevisi ye-CaryRx, futhi zilandelele isimo semithi kadokotela ngesikhathi sangempela ngephothali ye-CaryConnect.
I-CaryHealth iyinkampani yezobuchwepheshe bezokwelapha kanye nokunakekelwa kwempilo yedijithali esebenzisa ubuhlakani bokwenziwa ukuguqula indlela iziguli eziqala futhi zinamathela ngayo ekwelashweni. Ipulatifomu yethu ihlanganisa izinsizakalo zekhemisi, ukuzenzekela okuhlakaniphile, kanye nokuzibandakanya okuqhutshwa idatha ukuze kuthuthukiswe izinqubo zezempilo, kuthuthukiswe ukuqhubeka kokunakekelwa, futhi kunikezwe amandla iziguli kuyo yonke inkambo yokwelashwa. Ngokuvala igebe phakathi kwesayensi yokuphila, abahlinzeki bezempilo, kanye neziguli, i-CaryHealth ikhuthaza ukufinyelela okulinganayo ezinsizeni zezempilo futhi isiza ukwelashwa okuhlukahlukene ukufinyelela amandla akhona aphelele.
I-Cipher Pharmaceuticals (TSX: CPH) (OTCQX: CPHRF) iyinkampani ekhethekile yezokwelapha egxile ku-dermatology enephothifoliyo ecebile nehlukahlukene yemikhiqizo nemikhiqizo ethengiswayo ekuthuthukisweni kwesigaba sokuqala nesekugcineni. I-Cipher topical Natroba™ kanye nenguqulo yayo ejwayelekile enelayisensi, i-spinosad, yimikhiqizo kuphela ethole igama "elicacile" lama-scabies evela ku-US Food and Drug Administration (FDA). Ngaphezu kwalokho, i-Natroba™ (spinosad) iwukuphela kokwelashwa okuvunyelwe yi-FDA kwama-head lice okubonise ukusebenza kahle kakhulu kwezokwelapha uma kuqhathaniswa ne-Nix® (1% permethrin) ezivivinyweni ezimbili zezokwelapha zeSigaba III eziqhathaniswayo. Akukho ukuxubha amaqanda ama-lice okudingekayo.
Isikhathi sokuthunyelwe: Ephreli-28-2026
